Neoadjuvant chemotherapy in breast cancer:efficacy, response assessment and axillary strategy by Vriens, Birgitte Elisabeth Petronella Johanna
  
 
Neoadjuvant chemotherapy in breast cancer
Citation for published version (APA):
Vriens, BEPJ. (2017). Neoadjuvant chemotherapy in breast cancer: efficacy, response assessment and
axillary strategy. Maastricht: Maastricht University. https://doi.org/10.26481/dis.20171213bv





Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.































patients  in  relation  to  efficacy,  response  assessment  and  axillary  strategy.  Breast 
cancer is the most frequently diagnosed cancer and the leading cause of cancer death 
in  women  worldwide.  The  incidence  of  invasive  breast  cancer  in  the  Netherlands 
increased the last decades to 14,551 patients in 2015. Due to its high incidence, breast 
cancer  has  an  important  societal  and  economic  impact  in  the  Netherlands,  with 
annual incremental costs.  
Over the past decades we have seen a significant decrease of mortality of early breast 
cancer due  to early detection, multidisciplinary approach and  improved options  for 
systemic  treatment,  i.e.,  chemotherapy,  HER2  targeted  therapy  and  endocrine 













patient  subgroups  compared  to  concurrent  TAC  chemotherapy. Not  only  improved 
outcome, moreover, the  lower cumulative anthracycline dose with AC‐T  is attractive 
because of the lower risk of cardiotoxicity and risk of leukemia. Also, the reduced use 





surgical approach.  It  is  important that the clinical response predicts the pathological 
response accurately. We compared  the clinical  tumour size as assessed by magnetic 
resonance  imaging  (MRI) and ultrasound  (US) post neoadjuvant  chemotherapy with 
the  postoperative  pathologic  tumour  size.  MRI  and  US  showed  comparable 
(moderate) agreement with post chemotherapy pathological tumour size with a  low 
predictive  value especially  in ER‐positive  tumours. These data  are  relevant because 






facilitate breast  conserving  therapy  and bears  the opportunity of down  staging  the 
axilla  obviating  the  need  of  axillary  treatment  in  some  patients.  For  the  axilla,  the 
sentinel  node  biopsy  has  replaced  the  axillary  lymph  node  dissection  as  a  staging 
procedure.  Axillary  dissection  provides  excellent  regional  control  in  patients  with 
nodal  involvement,  but  is  associated  with  more  and  often  persistent  side‐effects, 
particularly  lymph edema and  restriction  in  shoulder mobility  compared  to  sentinel 
lymph node biopsy. In patients with clinical node negative disease, a negative sentinel 
node can identify the patients without residual axillary disease to spare axillary lymph 
node  dissection.  The  sentinel  node  can  be  performed  pre‐or  post  neoadjuvant 
chemotherapy.  Because  neoadjuvant  chemotherapy  has  shown  to  eradicate  nodal 
disease  in  20%  to  40%  of  patients,  performing  a  sentinel  node  procedure  post 
neoadjuvant  chemotherapy might  further de‐escalate  treatment. Based on our  and 
other studies, we conclude that in breast cancer patients with clinically node‐negative 
disease  the sentinel node procedure  is preferentially postponed  till after  the end of 
neoadjuvant  chemotherapy  to  take maximum  benefit  of  its  effect  on  nodal  down 
staging of subclinical disease. 
 
In  addition  to  the  academic  community,  especially  the  clinicians who  take  part  in 
multidisciplinary breast cancer treatment for breast cancer patients, the results of this 
thesis  are  relevant  for  newly  diagnosed  breast  cancer  patients with  indication  for 
systemic treatment because of the improved treatment option with least risk of long 
term toxicities. Also, the contents of this thesis are of interest to expert panels, which 
are  responsible  for  the development of  the national and  international guidelines  in 
breast cancer treatment. 
 
Further  research  is  needed  to  improve  treatment  options  for  patients with  breast 
cancer with enhanced attention to avoid overtreatment in patients with pCR in breast 
and  axilla  (de‐escalation)  as  well  as  on  improved  therapy  options  (escalation)  for 
patients with non‐pCR  in breast and axilla after standard neoadjuvant therapy. More 
research  is  needed  for  optimal  response  monitoring,  new  imaging  approaches  or 
combinations  of  existing  imaging  modalities  for  response  monitoring  could  be 
considered, possibly combined with biomarkers to predict the pathological response. 
 
In  conclusion,  this  thesis  provides  essential  data  of  several  aspects  of  neoadjuvant 
chemotherapy  in breast cancer patients  in relation  to efficacy, response assessment 
and  axillary  strategy.  These  data will  contribute  to  further  improvement  of  breast 
cancer treatment and outcome. 
 
 
